Volixibat clinical trials
Also written SHP626.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses volixibat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test volixibat.
- Jan 2027A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPhase 2 · Mirum Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses volixibat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)Active, not recruitingPhase 2Mirum Pharmaceuticals, Inc.NCT04663308Written as Volixibat
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingPhase 2Mirum Pharmaceuticals, Inc.NCT05050136Written as Volixibat
- A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)TerminatedPhase 2Mirum Pharmaceuticals, Inc.NCT04718961Written as Volixibat
- Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 2Mirum Pharmaceuticals, Inc.NCT02787304Written as SHP626
- A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One DoseCompletedPhase 1Mirum Pharmaceuticals, Inc.NCT02571192Written as SHP626
- Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid ExcretionCompletedPhase 1Mirum Pharmaceuticals, Inc.NCT02475317Written as Volixibat
- Safety and Tolerability Study of SHP626 in Overweight and Obese AdultsCompletedPhase 1Mirum Pharmaceuticals, Inc.NCT02287779Written as SHP626
Codes
What other systems call volixibat · ClinicalTrials.gg INT000966
- MeSH (NLM) C000627853volixibatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X2JZ0451H8VOLIXIBATConfirmed FDA, NLM, Wikidata
- Wikidata Q27293432volixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152907VolixibatOne source FDA
- DrugBank DB13914One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627853 | volixibat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X2JZ0451H8 | VOLIXIBAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27293432 | volixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152907 | Volixibat | One source FDA |
| DrugBank | DB13914 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.